|
ArQule has decided to major in molecular biology. The biotechnology firm had been providing chemistry services to help drugmakers discover new potential drug compounds. However, it has switched from being a helper to becoming a doer. Now ArQule is developing its own portfolio of oncology drugs, with a handful of anti-cancer compounds undergoing clinical trials. It is testing its most advanced candidate, ARQ 197, as a treatment for a variety of tumor types; and it is working with partner Roche on a handful of other anti-cancer compounds that reactivate the cellular functions that kill cancer cells.
|
| | | Contact Information | |
Address: |
19 Presidential Way
Woburn, MA 01801-5140
| | Phone: | 781-994-0300 | | Fax: | 781-376-6019 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 14.10 M | | Revenue Growth (1 yr): | 54.30% | | Employees (2008): | 107 | | Employee Growth (1 yr): | (-5.30%) |
|
|
Key People
| | • |
Chairman:
Patrick J. (Pat) Zenner
| | • |
CEO and Director:
Paolo Pucci
| | • |
President and COO:
Peter S. Lawrence
|
|
|
